Version 1
: Received: 25 March 2024 / Approved: 26 March 2024 / Online: 27 March 2024 (01:45:03 CET)
How to cite:
He, J.; Li, B.; Miao, C. Individual progression of S100 calcium-binding protein beta as a surrogate for epilepsy risk: rationale and design of a meta-analysis project. Preprints2024, 2024031564. https://doi.org/10.20944/preprints202403.1564.v1
He, J.; Li, B.; Miao, C. Individual progression of S100 calcium-binding protein beta as a surrogate for epilepsy risk: rationale and design of a meta-analysis project. Preprints 2024, 2024031564. https://doi.org/10.20944/preprints202403.1564.v1
He, J.; Li, B.; Miao, C. Individual progression of S100 calcium-binding protein beta as a surrogate for epilepsy risk: rationale and design of a meta-analysis project. Preprints2024, 2024031564. https://doi.org/10.20944/preprints202403.1564.v1
APA Style
He, J., Li, B., & Miao, C. (2024). Individual progression of S100 calcium-binding protein beta as a surrogate for epilepsy risk: rationale and design of a meta-analysis project. Preprints. https://doi.org/10.20944/preprints202403.1564.v1
Chicago/Turabian Style
He, J., Beilei Li and Chuhan Miao. 2024 "Individual progression of S100 calcium-binding protein beta as a surrogate for epilepsy risk: rationale and design of a meta-analysis project" Preprints. https://doi.org/10.20944/preprints202403.1564.v1
Abstract
Introduction: This study aims to elucidate the clinical diagnostic value of S100 Calcium Binding Protein beta (S100B) in epilepsy, a topic of ongoing debate among European and Asian epilepsy research centres.Methods and analysis: A structured long-term research plan was developed, comprising three phases. Phase one involves observational studies investigating the correlation between S100B levels in serum or cerebrospinal fluid and epilepsy. Phase two integrates observational and randomised controlled data to establish baseline S100B levels across diverse epilepsy demographics, underpinning the predictive value of S100B for epilepsy. Phase three focuses on randomised controlled trials to evaluate the diagnostic accuracy of S100B as an epilepsy biomarker.Ethics and dissemination:All enrolled patients will provide written consent. The ethics committee of the Second People’s Hospital of Gansu Province, Affiliated Hospital of Northwest Minzu University, China, approved the study (GSSEY2022-KY009-01).Registration: The study is registered with PROSPERO (CRD42023425431).
Keywords
S100B; Epilepsy; Biomarker; Diagnostic marker; Prognostic value
Subject
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
